FY2024 Earnings Forecast for Pfizer Issued By Zacks Research

Pfizer Inc. (NYSE:PFE - Free Report) - Research analysts at Zacks Research boosted their FY2024 earnings estimates for shares of Pfizer in a report released on Monday, November 18th. Zacks Research analyst K. Shah now anticipates that the biopharmaceutical company will post earnings of $2.87 per share for the year, up from their prior estimate of $2.57. The consensus estimate for Pfizer's current full-year earnings is $2.96 per share. Zacks Research also issued estimates for Pfizer's Q2 2026 earnings at $0.63 EPS, Q3 2026 earnings at $0.78 EPS and FY2026 earnings at $2.94 EPS.

Other analysts have also recently issued research reports about the stock. Citigroup assumed coverage on shares of Pfizer in a report on Friday, October 25th. They set a "neutral" rating and a $30.00 target price on the stock. Daiwa Capital Markets raised shares of Pfizer from a "neutral" rating to an "outperform" rating and upped their price target for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Evercore ISI raised Pfizer to a "strong-buy" rating in a research note on Wednesday, October 30th. Cantor Fitzgerald reissued an "overweight" rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Finally, Daiwa America raised shares of Pfizer from a "moderate buy" rating to a "strong-buy" rating in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $32.92.

Pfizer Stock Down 1.1 %

Shares of PFE traded down $0.28 on Wednesday, reaching $24.82. The stock had a trading volume of 19,485,789 shares, compared to its average volume of 38,326,508. The firm has a market capitalization of $140.65 billion, a price-to-earnings ratio of 33.70, a price-to-earnings-growth ratio of 0.79 and a beta of 0.67. The company has a 50-day simple moving average of $28.45 and a 200-day simple moving average of $28.63. Pfizer has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer's revenue was up 31.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.17) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PFE. Olistico Wealth LLC purchased a new stake in shares of Pfizer during the second quarter worth approximately $25,000. Gladius Capital Management LP grew its stake in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 38,015 shares in the last quarter. MFA Wealth Advisors LLC acquired a new stake in Pfizer in the second quarter valued at approximately $29,000. Quarry LP purchased a new stake in Pfizer during the 2nd quarter worth about $31,000. Finally, Financial Connections Group Inc. acquired a new position in shares of Pfizer in the 2nd quarter valued at $34,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb acquired 1,000 shares of the firm's stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares in the company, valued at $282,400. This represents a 11.11 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.06% of the stock is owned by insiders.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.77%. Pfizer's payout ratio is 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.